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colorectal cancer remains a leading cause of cancer-related death
worldwide. Most colorectal cancers develop from benign adenomas,
presenting an opportunity for early detection and intervention prior to
the onset of malignancy. For patients with early-stage tumours, ﬁve-
year survival rates are high. However, as early-stage tumours are typi-
cally asymptomatic, strategies to identify at risk individuals are critical
to enable early detection. Therefore, a key challenge is improving (the
currently suboptimal) patient uptake to screening programmes, as
well as the development of good prognostic and predictive biomarkers
for cancer risk and response to treatment. In this context and because of
the well-established role of prostaglandins in colorectal tumorigenesis
there are an increasing number of studies evaluating the utility of
circulating prostaglandins in association with cancer risk and disease
progression. In this issue of EBioMedicine, Li et al. (2015) provide evi-
dence suggesting that the measurement of circulating prostaglandins
in the blood may have potential utility in identifying patients at risk of
developing, or with, colorectal cancer. This is an attractive premise, as
a convenient blood-based test may increase uptake amongst eligible in-
dividuals that do not presently participate in current screening proce-
dures (such as the faecal occult blood test).
Prostaglandins are well-known to cancer biologists and have
attracted a lot of attention as important targets for chemoprevention
(Chan et al., 2005). They are generated by cyclooxygenase (COX)
enzymes (COX-1 and COX-2), which are targets of non-steroidal anti-
inﬂammatory drugs (NSAIDs) such as aspirin. COX-2 is known to be
upregulated in a size-dependent manner in about half of colorectal ad-
enomas and in the majority of colorectal cancers, leading to increased
PGE2 levels (Eberhart et al., 1994; Elder et al., 2002). PGE2 has a major
inﬂuence on colorectal tumour biology (Greenhough et al., 2009), and
the chemopreventive action of NSAIDs is thought to be mediated, at
least in part, by blocking PGE2 production. A number of studies have
highlighted that PGE-M, a urinary PGE2metabolite that reﬂects system-
ic PGE2 levels, could serve as a prognostic biomarker in colorectal,
gastric, and more recently breast cancers (Dong et al., 2009; Johnson
et al., 2006; Wang and DuBois, 2013).
At present, it is not clear whether prostaglandins other than PGE-M
could also serve as prognostic or predictive biomarkers for colorectal
cancer. To examine this, Li et al. took blood samples from healthy indi-
viduals, as well as from patients with familial adenomatous polyposisDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2014.12.004.
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cancer. The authors then examined the levels of circulating PGE2,
PGD2, PGF2α, PGI2 and thromboxane A2 [TXA2] — in most cases by
measuring their stable metabolites as surrogates. Perhaps surprisingly,
the authors only observed a modest increase in circulating PGE2 (and
PGD2) levels in FAP patients, but the levels of TXA2 (inferred by mea-
surement of itsmore stable derivative TXB2)were dramatically elevated
in both FAP and sporadic colorectal cancer patients relative to healthy
individuals. These observations were conﬁrmed by measuring TXA2
levels in the urine of colorectal cancer patients (by measuring 11-
dehydro-TXB2) and are consistent with a previous report of increased
urinary TXA2 in FAP patients (Dovizio et al., 2012). The authors went
on to show that the majority of patients with colorectal cancer in their
study could be identiﬁed bymeasuring circulating TXA2 levels, and sug-
gest that TXA2 levels may therefore have prognostic value in colorectal
cancer patients.
What could account for the high levels of circulating TXA2 in patients
with colorectal cancer? Could there be a role for TXA2 signalling in
tumour development? In an effort to understand this, Li et al. performed
immunohistochemistry on patient colorectal tumour biopsies to exam-
ine the expression of TXA2 synthase (TBXAS1), an important enzyme for
TXA2 production (Li et al., 2015). Expression of TBXAS1wasupregulated
in tumour tissue, as was the TXA2 receptor (TBXA2R), raising the possi-
bility that they have a functional role in tumour development. In a series
of in vitro experiments using colorectal cancer cells, the authors found
that RNAi-mediated depletion of either TBXAS1 or TBXA2R resulted in
decreased anchorage-independent growth— suggestive of reducedma-
lignant potential. These ﬁndings are consistent with a previous study in
which enforced expression of TBXAS1 accelerated tumour growth and
angiogenesis in vivo (Pradono et al., 2002). Finally, the authors asked
whether aspirin might target TXA2 signalling as part of its chemopre-
ventive action. Tumour biopsies from FAP patients grouped into aspirin
users and non-users revealed an association between reduced TBXAS1
and TBXA2R expression and aspirin use. In support of these data, aspirin
treatment of colorectal cancer cell lines in vitro decreased the protein
expression of TBXAS1 and TBXA2R.
The ﬁndings of Li et al. highlight the possibility that the measure-
ment of circulating prostaglandins might be useful in cancer screening
and prevention, but naturally there are caveats (Li et al., 2015). The
study used small patient numbers, so further validation will be neces-
sary to determine the usefulness of circulating TXA2 as a prognostic or
predictive biomarker, and the study does not address the role of con-
founding factors such as inﬂammation and infection. Furthermore, it isthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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made to the level detected in the circulation. Does exogenous TXA2
(or a stable analogue) promote colorectal tumour cell growth in vitro
andwould this rescue the inhibitory effects of TBXAS1-depletion the au-
thors observe on anchorage-independent growth? If so, what signal
transduction pathways are activated by TXA2 in colorectal tumour
cells? It will also be interesting to determine whether circulating TXA2
levels can be used to report the efﬁcacy of NSAIDs in cancer prevention
and/or an adjuvant setting.
In summary, there ismuch to do before TXA2metabolites are used as
biomarkers for cancer screening, but with careful validation in larger
patient populations the case for using circulating prostaglandins as
biomarkers for early detection, disease progression and response to
treatment is gaining momentum.
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